Your browser doesn't support javascript.
loading
First amyloid ß1-42 certified reference material for re-calibrating commercial immunoassays.
Boulo, Sébastien; Kuhlmann, Julia; Andreasson, Ulf; Brix, Britta; Venkataraman, Iswariya; Herbst, Victor; Rutz, Sandra; Manuilova, Ekaterina; Vandijck, Manu; Dekeyser, Filip; Bjerke, Maria; Pannee, Josef; Charoud-Got, Jean; Auclair, Guy; Mazoua, Stéphane; Pinski, Gregor; Trapmann, Stefanie; Schimmel, Heinz; Emons, Hendrik; Quaglia, Milena; Portelius, Erik; Korecka, Magdalena; Shaw, Leslie M; Lame, Mary; Chambers, Erin; Vanderstichele, Hugo; Stoops, Erik; Leinenbach, Andreas; Bittner, Tobias; Jenkins, Rand G; Kostanjevecki, Vesna; Lewczuk, Piotr; Gobom, Johan; Zetterberg, Henrik; Zegers, Ingrid; Blennow, Kaj.
Afiliación
  • Boulo S; European Commission, Joint Research Centre (JRC), Geel, Belgium.
  • Kuhlmann J; European Commission, Joint Research Centre (JRC), Geel, Belgium.
  • Andreasson U; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Brix B; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Venkataraman I; EUROIMMUN AG, Luebeck, Germany.
  • Herbst V; EUROIMMUN US Inc., Mountain Lakes, New Jersey, USA.
  • Rutz S; EUROIMMUN AG, Luebeck, Germany.
  • Manuilova E; Roche Diagnostics GmbH, Penzberg, Germany.
  • Vandijck M; Roche Diagnostics GmbH, Penzberg, Germany.
  • Dekeyser F; Fujirebio Europe N.V., Ghent, Belgium.
  • Bjerke M; Fujirebio Europe N.V., Ghent, Belgium.
  • Pannee J; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Charoud-Got J; Neurochemistry Laboratory, Department of Clinical Biology and Center for Neurosciences, UZ Brussel and Vrije Universiteit Brussel, Brussels, Belgium.
  • Auclair G; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Mazoua S; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Pinski G; European Commission, Joint Research Centre (JRC), Geel, Belgium.
  • Trapmann S; European Commission, Joint Research Centre (JRC), Geel, Belgium.
  • Schimmel H; European Commission, Joint Research Centre (JRC), Geel, Belgium.
  • Emons H; European Commission, Joint Research Centre (JRC), Geel, Belgium.
  • Quaglia M; European Commission, Joint Research Centre (JRC), Geel, Belgium.
  • Portelius E; European Commission, Joint Research Centre (JRC), Geel, Belgium.
  • Korecka M; European Commission, Joint Research Centre (JRC), Geel, Belgium.
  • Shaw LM; LGC Limited, NML, Teddington, UK.
  • Lame M; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Chambers E; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Vanderstichele H; Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Stoops E; Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Leinenbach A; Waters Corporation, Milford, Massachusetts, USA.
  • Bittner T; Waters Corporation, Milford, Massachusetts, USA.
  • Jenkins RG; ADx NeuroSciences NV, Ghent, Belgium.
  • Kostanjevecki V; Biomarkable bvba, Ghent, Belgium.
  • Lewczuk P; ADx NeuroSciences NV, Ghent, Belgium.
  • Gobom J; Roche Diagnostics GmbH, Penzberg, Germany.
  • Zetterberg H; F.Hoffmann-LaRoche, Basel, Switzerland.
  • Zegers I; PPD Laboratories, Department of Chromatographic Sciences, Richmond, Virginia, USA.
  • Blennow K; Fujirebio Europe N.V., Ghent, Belgium.
Alzheimers Dement ; 16(11): 1493-1503, 2020 11.
Article en En | MEDLINE | ID: mdl-32755010
ABSTRACT

INTRODUCTION:

Reference materials based on human cerebrospinal fluid were certified for the mass concentration of amyloid beta (Aß)1-42 (Aß42 ). They are intended to be used to calibrate diagnostic assays for Aß42 .

METHODS:

The three certified reference materials (CRMs), ERM-DA480/IFCC, ERM-DA481/IFCC and ERM-DA482/IFCC, were prepared at three concentration levels and characterized using isotope dilution mass spectrometry methods. Roche, EUROIMMUN, and Fujirebio used the three CRMs to re-calibrate their immunoassays.

RESULTS:

The certified Aß42 mass concentrations in ERM-DA480/IFCC, ERM-DA481/IFCC, and ERM-DA482/IFCC are 0.45, 0.72, and 1.22 µg/L, respectively, with expanded uncertainties (k = 2) of 0.07, 0.11, and 0.18 µg/L, respectively. Before re-calibration, a good correlation (Pearson's r > 0.97), yet large biases, were observed between results from different commercial assays. After re-calibration the between-assay bias was reduced to < 5%.

DISCUSSION:

The Aß42 CRMs can ensure the equivalence of results between methods and across platforms for the measurement of Aß42 .
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoensayo / Péptidos beta-Amiloides Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2020 Tipo del documento: Article País de afiliación: Bélgica

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Inmunoensayo / Péptidos beta-Amiloides Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2020 Tipo del documento: Article País de afiliación: Bélgica